Skip to main content
Top
Published in: Journal of Assisted Reproduction and Genetics 3/2019

01-03-2019 | Fertility Preservation

Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved

Authors: Francesca Filippi, Fabio Martinelli, Alessio Paffoni, Marco Reschini, Francesco Raspagliesi, Edgardo Somigliana

Published in: Journal of Assisted Reproduction and Genetics | Issue 3/2019

Login to get access

Abstract

Purpose

To evaluate the capacity of random antral follicle count (AFC), i.e., AFC recorded at any time during the menstrual cycle, to predict the number of retrieved mature oocytes in women with malignancies undergoing random start ovarian hyperstimulation

Methods

A consecutive series of 72 women with malignancies who underwent ovarian hyperstimulation aimed at egg freezing between July 2014 and December 2016 was retrospectively reviewed. A standardized random start protocol was used for all women. AFC and serum AMH were systematically assessed prior to initiating ovarian hyperstimulation. The main outcome was the retrieval of ≥ 10 mature oocytes. The accuracy of random AFC was tested with the c-statistics (area under the ROC curve).

Results

For the whole cohort, the c-statistics for the prediction of ≥ 10 mature oocytes using AFC and serum AMH were similar. Specifically, the areas under the curve were 0.76 (95%CI 0.66–0.87) and 0.82 (95%CI 0.72–0.92), respectively (p = ns). Moreover, when considering the subgroup of women recruited after day 5 of the cycle (proper random start, n = 52), the areas under the curve did not also differ. Specifically, they resulted in 0.77 (95%CI 0.64–0.89) and 0.83 (95%CI 0.72–0.95), respectively (p = ns).

Conclusions

AFC collected at any time during the menstrual cycle can provide valuable information for the counseling of women with malignancies scheduled for oocyte cryopreservation. Its reliability appears to be non-inferior to that of serum AMH.
Literature
1.
go back to reference Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge A, et al. For patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.CrossRefPubMedPubMedCentral Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge A, et al. For patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.CrossRefPubMedPubMedCentral
2.
go back to reference Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. Fertility preservation in cancer patients: the global framework. Cancer Treat Rev. 2014;40:1019–27.CrossRefPubMed Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. Fertility preservation in cancer patients: the global framework. Cancer Treat Rev. 2014;40:1019–27.CrossRefPubMed
4.
go back to reference Chan JL, Johnson LN, Efymow BL, Sammel MD, Gracia CR. Outcomes of ovarian stimulation after treatment with chemotherapy. J Assist Reprod Genet. 2015;32:1537–45.CrossRefPubMedPubMedCentral Chan JL, Johnson LN, Efymow BL, Sammel MD, Gracia CR. Outcomes of ovarian stimulation after treatment with chemotherapy. J Assist Reprod Genet. 2015;32:1537–45.CrossRefPubMedPubMedCentral
5.
go back to reference Fisch B, Abir R. Female fertility preservation: past, present and future. Reproduction. 2018;156:F11–27.CrossRefPubMed Fisch B, Abir R. Female fertility preservation: past, present and future. Reproduction. 2018;156:F11–27.CrossRefPubMed
6.
go back to reference Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2018;33:2051–59. Alvarez RM, Ramanathan P. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response. Hum Reprod. 2018;33:2051–59.
7.
go back to reference Lefebvre T, Mirallié S, Leperlier F, Reignier A, Barrière P, Fréour T. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type. Reprod BioMed Online. 2018;37:201–7.CrossRefPubMed Lefebvre T, Mirallié S, Leperlier F, Reignier A, Barrière P, Fréour T. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type. Reprod BioMed Online. 2018;37:201–7.CrossRefPubMed
8.
go back to reference Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33:181–7.CrossRefPubMed Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33:181–7.CrossRefPubMed
9.
go back to reference Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19:26–36.CrossRefPubMed Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19:26–36.CrossRefPubMed
10.
go back to reference Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105:755–64.CrossRefPubMed Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105:755–64.CrossRefPubMed
11.
go back to reference Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99:963–9.CrossRefPubMed Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99:963–9.CrossRefPubMed
12.
go back to reference Li HW, Wong BP, Ip WK, Yeung WS, Ho PC, Ng EH. Comparative evaluation of three new commercial immunoassays for anti-Müllerian hormone measurement. Hum Reprod. 2016;31:2796–802.CrossRefPubMed Li HW, Wong BP, Ip WK, Yeung WS, Ho PC, Ng EH. Comparative evaluation of three new commercial immunoassays for anti-Müllerian hormone measurement. Hum Reprod. 2016;31:2796–802.CrossRefPubMed
13.
go back to reference Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet. 2011;28:651–6.CrossRefPubMedPubMedCentral Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet. 2011;28:651–6.CrossRefPubMedPubMedCentral
14.
go back to reference Martins WP, Kollmann M, Raine-Fenning N. Counting ovarian follicles: updated threshold for diagnosis of hyperandrogenic anovulation. Ultrasound Obstet Gynecol. 2014;44:131–4.CrossRefPubMed Martins WP, Kollmann M, Raine-Fenning N. Counting ovarian follicles: updated threshold for diagnosis of hyperandrogenic anovulation. Ultrasound Obstet Gynecol. 2014;44:131–4.CrossRefPubMed
15.
go back to reference van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, et al. Comparison of inter and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25:221–7.CrossRefPubMed van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC, et al. Comparison of inter and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25:221–7.CrossRefPubMed
16.
go back to reference Mavrelos D, Al Chami A, Talaulikar V, Burt E, Webber L, Ploubidis G, et al. Variation in antral follicle counts at different times in the menstrual cycle: does it matter? Reprod BioMed Online. 2016;33:174–9.CrossRefPubMed Mavrelos D, Al Chami A, Talaulikar V, Burt E, Webber L, Ploubidis G, et al. Variation in antral follicle counts at different times in the menstrual cycle: does it matter? Reprod BioMed Online. 2016;33:174–9.CrossRefPubMed
17.
go back to reference Rombauts L, Onwude JL, Chew HW, Vollenhoven BJ. The predictive value of antral follicle count remains unchanged across the menstrual cycle. Fertil Steril. 2011;96:1514–8.CrossRefPubMed Rombauts L, Onwude JL, Chew HW, Vollenhoven BJ. The predictive value of antral follicle count remains unchanged across the menstrual cycle. Fertil Steril. 2011;96:1514–8.CrossRefPubMed
18.
go back to reference Broekmans FJ, De Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010;94:1044–51.CrossRefPubMed Broekmans FJ, De Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010;94:1044–51.CrossRefPubMed
19.
go back to reference Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100:1673–80.CrossRefPubMed Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100:1673–80.CrossRefPubMed
20.
go back to reference Grynberg M, Poulain M, le Parco S, Sifer C, Fanchin R, Frydman N. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Hum Reprod. 2016;31:623–9.CrossRefPubMed Grynberg M, Poulain M, le Parco S, Sifer C, Fanchin R, Frydman N. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Hum Reprod. 2016;31:623–9.CrossRefPubMed
21.
go back to reference Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1–12.CrossRefPubMed Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1–12.CrossRefPubMed
22.
go back to reference Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod. 2012;27:1606–12.CrossRefPubMed Rienzi L, Cobo A, Paffoni A, Scarduelli C, Capalbo A, Vajta G, et al. Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod. 2012;27:1606–12.CrossRefPubMed
23.
go back to reference Sarais V, Paffoni A, Pagliardini L, Filippi F, Martinelli F, Mangili G, et al. Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer. Acta Obstet Gynecol Scand. 2017;96:949–53.CrossRefPubMed Sarais V, Paffoni A, Pagliardini L, Filippi F, Martinelli F, Mangili G, et al. Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer. Acta Obstet Gynecol Scand. 2017;96:949–53.CrossRefPubMed
25.
go back to reference Somigliana E, Lattuada D, Colciaghi B, Filippi F, La Vecchia I, Tirelli A, et al. Serum anti-Müllerian hormone in subfertile women. Acta Obstet Gynecol Scand. 2015;94:1307–12.CrossRefPubMed Somigliana E, Lattuada D, Colciaghi B, Filippi F, La Vecchia I, Tirelli A, et al. Serum anti-Müllerian hormone in subfertile women. Acta Obstet Gynecol Scand. 2015;94:1307–12.CrossRefPubMed
27.
go back to reference Nastri CO, Teixeira DM, Moroni RM, Leitao VM, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45:377–93.CrossRefPubMed Nastri CO, Teixeira DM, Moroni RM, Leitao VM, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45:377–93.CrossRefPubMed
28.
go back to reference Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21:698–710.CrossRefPubMed Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21:698–710.CrossRefPubMed
29.
go back to reference Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32:568–74.PubMed Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017;32:568–74.PubMed
30.
go back to reference Metzger ML, Meacham LR, Patterson B, Casillas JS, Constine LS, Hijiya N, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31:1239–47.CrossRefPubMedPubMedCentral Metzger ML, Meacham LR, Patterson B, Casillas JS, Constine LS, Hijiya N, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013;31:1239–47.CrossRefPubMedPubMedCentral
31.
go back to reference Birch Petersen K, Hvidman HW, Forman JL, Pinborg A, Larsen EC, Macklon KT, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Hum Reprod. 2015;30:2364–75.CrossRefPubMed Birch Petersen K, Hvidman HW, Forman JL, Pinborg A, Larsen EC, Macklon KT, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Hum Reprod. 2015;30:2364–75.CrossRefPubMed
32.
go back to reference Benaglia L, Candotti G, Busnelli A, Paffoni A, Vercellini P, Somigliana E. Antral follicle count as a predictor of ovarian responsiveness in women with endometriomas or with a history of surgery for endometriomas. Fertil Steril. 2015;103:1544–50.CrossRefPubMed Benaglia L, Candotti G, Busnelli A, Paffoni A, Vercellini P, Somigliana E. Antral follicle count as a predictor of ovarian responsiveness in women with endometriomas or with a history of surgery for endometriomas. Fertil Steril. 2015;103:1544–50.CrossRefPubMed
33.
go back to reference Lima ML, Martins WP, Coelho Neto MA, Nastri CO, Ferriani RA, Navarro PA. Assessment of ovarian reserve by antral follicle count in ovaries with endometrioma. Ultrasound Obstet Gynecol. 2015;46:239–42.CrossRefPubMed Lima ML, Martins WP, Coelho Neto MA, Nastri CO, Ferriani RA, Navarro PA. Assessment of ovarian reserve by antral follicle count in ovaries with endometrioma. Ultrasound Obstet Gynecol. 2015;46:239–42.CrossRefPubMed
34.
go back to reference La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30.CrossRefPubMed La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30.CrossRefPubMed
35.
go back to reference Subirá J, Alberola-Rubio J, Núñez MJ, Escrivá AM, Pellicer A, Montañana V, et al. Inter-cycle and inter-observer variability of the antral follicle count in routine clinical practice. Gynecol Endocrinol. 2017;33:515–8.CrossRefPubMed Subirá J, Alberola-Rubio J, Núñez MJ, Escrivá AM, Pellicer A, Montañana V, et al. Inter-cycle and inter-observer variability of the antral follicle count in routine clinical practice. Gynecol Endocrinol. 2017;33:515–8.CrossRefPubMed
36.
go back to reference Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20:688–701.CrossRefPubMed Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20:688–701.CrossRefPubMed
Metadata
Title
Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved
Authors
Francesca Filippi
Fabio Martinelli
Alessio Paffoni
Marco Reschini
Francesco Raspagliesi
Edgardo Somigliana
Publication date
01-03-2019
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 3/2019
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-018-1377-0

Other articles of this Issue 3/2019

Journal of Assisted Reproduction and Genetics 3/2019 Go to the issue